Icon Wealth Advisors LLC Sells 7,801 Shares of Zoetis Inc. $ZTS

Icon Wealth Advisors LLC trimmed its position in Zoetis Inc. (NYSE:ZTS) by 32.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 16,602 shares of the company’s stock after selling 7,801 shares during the quarter. Icon Wealth Advisors LLC’s holdings in Zoetis were worth $2,095,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Global Wealth Strategies & Associates bought a new stake in shares of Zoetis in the 4th quarter valued at about $25,000. Lodestone Wealth Management LLC acquired a new position in Zoetis in the 4th quarter valued at about $30,000. KERR FINANCIAL PLANNING Corp acquired a new position in Zoetis in the 3rd quarter valued at about $31,000. Holos Integrated Wealth LLC acquired a new position in Zoetis in the 4th quarter valued at about $32,000. Finally, Elyxium Wealth LLC acquired a new position in Zoetis in the 4th quarter valued at about $32,000. 92.80% of the stock is owned by institutional investors.

Zoetis Stock Down 2.3%

Shares of ZTS opened at $79.51 on Friday. Zoetis Inc. has a 12 month low of $72.38 and a 12 month high of $167.38. The firm’s 50 day moving average is $96.94 and its 200-day moving average is $114.22. The stock has a market capitalization of $33.33 billion, a PE ratio of 13.19, a P/E/G ratio of 1.24 and a beta of 0.75. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The business had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.30 billion. During the same period in the prior year, the business posted $1.48 earnings per share. The firm’s revenue for the quarter was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Equities research analysts forecast that Zoetis Inc. will post 6.88 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be issued a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 annualized dividend and a dividend yield of 2.7%. Zoetis’s dividend payout ratio (DPR) is currently 35.16%.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on ZTS shares. Wall Street Zen lowered shares of Zoetis from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. UBS Group decreased their price target on shares of Zoetis from $130.00 to $99.00 and set a “neutral” rating on the stock in a research note on Friday, May 8th. BTIG Research reiterated a “buy” rating and issued a $160.00 price target on shares of Zoetis in a research note on Thursday, February 26th. JPMorgan Chase & Co. decreased their price target on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Finally, Leerink Partners reiterated a “market perform” rating on shares of Zoetis in a research note on Tuesday, March 10th. Six research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $133.92.

Key Zoetis News

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: The recent analyst coverage split suggests some Wall Street firms still see value in Zoetis despite the recent selloff, which could help stabilize sentiment. Zoetis (ZTS) Stock Draws Fresh Price Target Split After Difficult Q1 Update
• Neutral Sentiment: Multiple law firms are urging investors who bought Zoetis shares between January 14, 2025 and May 6, 2026 to join or lead securities-fraud litigation ahead of the July 27 deadline; while procedural for now, the steady stream of notices keeps legal overhang in focus. Zoetis Inc. (ZTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
• Neutral Sentiment: Additional class-action reminders from The Gross Law Firm, Bragar Eagel & Squire, and The Schall Law Firm add to the headline noise, but do not yet change Zoetis’s fundamentals on their own. ZTS Shareholder Alert: Zoetis Inc. Securities Class Action Lawsuit
• Neutral Sentiment: The lawsuits appear to center on alleged misrepresentations about weakening veterinarian adoption and prescription trends, which help explain why investors remain cautious after the company’s disappointing Q1 results. Lost Money on Zoetis Inc. (ZTS)? Join Class Action Suit Seeking Recovery
• Negative Sentiment: The legal overhang and repeated fraud allegations are a negative for sentiment and may keep pressure on Zoetis Inc. (NYSE: ZTS) until there is more clarity on the lawsuits and on whether the underlying business trends are improving. ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Zoetis Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ZTS

Insider Transactions at Zoetis

In other Zoetis news, Director Frank A. Damelio bought 6,650 shares of the stock in a transaction dated Wednesday, May 13th. The shares were bought at an average cost of $75.39 per share, with a total value of $501,343.50. Following the completion of the acquisition, the director owned 21,458 shares of the company’s stock, valued at $1,617,718.62. This trade represents a 44.91% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Paul Bisaro bought 2,000 shares of the stock in a transaction dated Wednesday, May 13th. The shares were acquired at an average cost of $75.88 per share, for a total transaction of $151,760.00. Following the completion of the acquisition, the director directly owned 27,862 shares of the company’s stock, valued at approximately $2,114,168.56. This trade represents a 7.73% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders have acquired 11,650 shares of company stock valued at $886,384. 0.22% of the stock is currently owned by company insiders.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.